{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:40:08Z","timestamp":1792798808231,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"DOI":"10.1007\/s11657-026-01797-4","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T10:25:23Z","timestamp":1792751123000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patients\u2019 lived experiences of fractures during immune checkpoint inhibitor therapy: a qualitative study"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1524-3753","authenticated-orcid":false,"given":"Mahdi","family":"Neshan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1824-9050","authenticated-orcid":false,"given":"Maira","family":"Quintanilha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nese","family":"Yuksel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4814-3126","authenticated-orcid":false,"given":"Quincy","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4411-0581","authenticated-orcid":false,"given":"Matthew","family":"Anaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3937-3782","authenticated-orcid":false,"given":"Michael","family":"Kolinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3163-9902","authenticated-orcid":false,"given":"Naveen S.","family":"Basappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3006-6145","authenticated-orcid":false,"given":"John","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9858-5398","authenticated-orcid":false,"given":"Carrie","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"1797_CR1","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA et al (2022) Immune checkpoint inhibitors in cancer therapy. Curr Oncol 29:3044\u20133060","journal-title":"Curr Oncol"},{"key":"1797_CR2","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41416-023-02181-6","volume":"128","author":"RJ Walsh","year":"2023","unstructured":"Walsh RJ, Sundar R, Lim JSJ (2023) Immune checkpoint inhibitor combinations-current and emerging strategies. Br J Cancer 128:1415\u20131417","journal-title":"Br J Cancer"},{"key":"1797_CR3","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1158\/2159-8290.CD-20-1209","volume":"11","author":"TA Yap","year":"2021","unstructured":"Yap TA, Parkes EE, Peng W et al (2021) Development of immunotherapy combination strategies in cancer. Cancer Discov 11:1368\u20131397","journal-title":"Cancer Discov"},{"key":"1797_CR4","doi-asserted-by":"publisher","first-page":"5490","DOI":"10.3390\/ijms25105490","volume":"25","author":"J Qiu","year":"2024","unstructured":"Qiu J, Cheng Z, Jiang Z et al (2024) Immunomodulatory precision: A narrative review exploring the critical role of immune checkpoint inhibitors in cancer treatment. Int J Mol Sci 25:5490","journal-title":"Int J Mol Sci"},{"key":"1797_CR5","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158\u2013168","journal-title":"N Engl J Med"},{"key":"1797_CR6","doi-asserted-by":"crossref","unstructured":"Ye C, Jamal S, Hudson M, Fifi-Mah A (2019) Immune checkpoint inhibitor associated rheumatic adverse events: a review of their presentations and treatments. Curr Treatment Options 5:272\u2013289","DOI":"10.1007\/s40674-019-00131-z"},{"key":"1797_CR7","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3899\/jrheum.190084","volume":"47","author":"S Jamal","year":"2020","unstructured":"Jamal S, Hudson M, Fifi-Mah A, Ye C (2020) Immune-related adverse events associated with cancer immunotherapy: a review for the practicing rheumatologist. J Rheumatol 47:166\u2013175","journal-title":"J Rheumatol"},{"key":"1797_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102595","volume":"19","author":"J Roberts","year":"2020","unstructured":"Roberts J, Ennis D, Hudson M et al (2020) Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort. Autoimmun Rev 19:102595","journal-title":"Autoimmun Rev"},{"key":"1797_CR9","doi-asserted-by":"publisher","unstructured":"Roberts J, Barmettler S, Murray J et al (2024) Musculoskeletal immune-related adverse events of PD-(L)1 inhibitors in melanoma: a systematic review and meta-analysis. Immunotherapy 16:1247\u20131254. https:\/\/doi.org\/10.1080\/1750743X.2024.2436838","DOI":"10.1080\/1750743X.2024.2436838"},{"key":"1797_CR10","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1093\/rheumatology\/keae343","volume":"64","author":"AR Bass","year":"2025","unstructured":"Bass AR, Xie F, Jannat-Khah D et al (2025) Incidence of checkpoint inhibitor-associated inflammatory arthritis, immunomodulation and mortality in cancer patients on immunotherapy: a retrospective cohort study. Rheumatology (Oxford) 64:1637\u20131642","journal-title":"Rheumatology (Oxford)"},{"key":"1797_CR11","first-page":"108","volume":"52","author":"M Elsayed","year":"2025","unstructured":"Elsayed M, Greenwood B, Wang X et al (2025) Fracture Risk Associated with Immune Checkpoint Inhibitors. A Systematic Literature Review and Meta-Analysis 52:108\u2013109","journal-title":"A Systematic Literature Review and Meta-Analysis"},{"key":"1797_CR12","doi-asserted-by":"publisher","first-page":"e009309","DOI":"10.1136\/jitc-2024-009309","volume":"12","author":"M Elsayed","year":"2024","unstructured":"Elsayed M, Ye C (2024) Osteoporotic fractures: an unrecognized adverse event of immune checkpoint inhibitors? J Immunother Cancer 12:e009309","journal-title":"J Immunother Cancer"},{"key":"1797_CR13","doi-asserted-by":"publisher","unstructured":"Siampanopoulou V, Ziogas DC, Lyrarakis G, et al (2025) Bone mineral density changes following immune checkpoint inhibitor therapy: insights from a case series analysis. Osteoporos Int. https:\/\/doi.org\/10.1007\/s00198-025-07647-2","DOI":"10.1007\/s00198-025-07647-2"},{"key":"1797_CR14","doi-asserted-by":"publisher","first-page":"e000398","DOI":"10.1136\/bmjonc-2024-000398","volume":"3","author":"C Ye","year":"2024","unstructured":"Ye C, Zhao B, Leslie WD et al (2024) Increase in major osteoporotic fractures after therapy with immune checkpoint inhibitors. BMJ Oncol 3:e000398","journal-title":"BMJ Oncol"},{"key":"1797_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2022.100459","volume":"37","author":"F Pantano","year":"2022","unstructured":"Pantano F, Tramontana F, Iuliani M et al (2022) Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: An exploratory analysis. J Bone Oncol 37:100459","journal-title":"J Bone Oncol"},{"key":"1797_CR16","doi-asserted-by":"publisher","unstructured":"Ye C, Lee K, Leslie WD, et al (2023) Fracture rate increases after immune checkpoint inhibitor treatment: a potential new immune related adverse event. Osteoporos Int. https:\/\/doi.org\/10.1007\/s00198-023-06690-1","DOI":"10.1007\/s00198-023-06690-1"},{"key":"1797_CR17","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1093\/jbmr\/zjaf009","volume":"40","author":"BE Matheson","year":"2025","unstructured":"Matheson BE, Jaremko JL, Dowhanik A et al (2025) Assessing the effects of immune checkpoint inhibitors on bone utilizing machine learning-assisted opportunistic quantitative computed tomography. J Bone Miner Res 40:396\u2013403","journal-title":"J Bone Miner Res"},{"key":"1797_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1199031","volume":"14","author":"H Liu","year":"2023","unstructured":"Liu H, Li Y, Li J et al (2023) Musculoskeletal adverse events induced by immune checkpoint inhibitors: a large-scale pharmacovigilance study. Front Pharmacol 14:1199031","journal-title":"Front Pharmacol"},{"key":"1797_CR19","doi-asserted-by":"publisher","first-page":"e000868","DOI":"10.1136\/bmjonc-2025-000868","volume":"4","author":"MP Yavropoulou","year":"2025","unstructured":"Yavropoulou MP, Anastasilakis DA, Kasdagli M-I et al (2025) Incidence of fractures in patients with solid cancers treated with immune checkpoint inhibitors: a systematic review and meta-analysis of randomised controlled trials. BMJ Oncol 4:e000868","journal-title":"BMJ Oncol"},{"key":"1797_CR20","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1359\/jbmr.2001.16.2.328","volume":"16","author":"MN Weitzmann","year":"2001","unstructured":"Weitzmann MN, Cenci S, Rifas L et al (2001) T cell activation induces human osteoclast formation via receptor activator of nuclear factor kappaB ligand-dependent and -independent mechanisms. J Bone Miner Res 16:328\u2013337","journal-title":"J Bone Miner Res"},{"key":"1797_CR21","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD et al (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39:4073\u20134126","journal-title":"J Clin Oncol"},{"key":"1797_CR22","doi-asserted-by":"publisher","unstructured":"G\u00fcven DC, Thong MS, Arndt V (2024) Survivorship outcomes in patients treated with immune checkpoint inhibitors: a scoping review. J Cancer Surviv. https:\/\/doi.org\/10.1007\/s11764-023-01507-w","DOI":"10.1007\/s11764-023-01507-w"},{"key":"1797_CR23","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1359\/jbmr.061113","volume":"22","author":"R Burge","year":"2007","unstructured":"Burge R, Dawson-Hughes B, Solomon DH et al (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 22:465\u2013475","journal-title":"J Bone Miner Res"},{"key":"1797_CR24","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","volume":"17","author":"O Johnell","year":"2006","unstructured":"Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726\u20131733","journal-title":"Osteoporos Int"},{"key":"1797_CR25","doi-asserted-by":"publisher","first-page":"380","DOI":"10.7326\/0003-4819-152-6-201003160-00008","volume":"152","author":"P Haentjens","year":"2010","unstructured":"Haentjens P, Magaziner J, Col\u00f3n-Emeric CS et al (2010) Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 152:380\u2013390","journal-title":"Ann Intern Med"},{"key":"1797_CR26","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/jgs.15207","volume":"66","author":"BS L Riska","year":"2018","unstructured":"L Riska BS, Fors\u00e9n L, Omsland TK et al (2018) Does the association of comorbidity with 1-year mortality after hip fracture differ according to gender? The Norwegian epidemiologic osteoporosis studies (NOREPOS). J Am Geriatr Soc 66:553\u2013558","journal-title":"J Am Geriatr Soc"},{"key":"1797_CR27","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00590-022-03250-x","volume":"33","author":"S Katsanos","year":"2023","unstructured":"Katsanos S, Sioutis S, Reppas L et al (2023) What do hip fracture patients die from? Eur J Orthop Surg Traumatol 33:751\u2013757","journal-title":"Eur J Orthop Surg Traumatol"},{"key":"1797_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0074492","volume":"8","author":"M Van Hemelrijck","year":"2013","unstructured":"Van Hemelrijck M, Garmo H, Micha\u00eblsson K et al (2013) Mortality following hip fracture in men with prostate cancer. PLoS One 8:e74492","journal-title":"PLoS One"},{"key":"1797_CR29","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1007\/s00198-022-06542-4","volume":"33","author":"C Ye","year":"2022","unstructured":"Ye C, Leslie WD, Al-Azazi S et al (2022) Fractures and long-term mortality in cancer patients: a population-based cohort study. Osteoporos Int 33:2629\u20132635","journal-title":"Osteoporos Int"},{"key":"1797_CR30","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s00520-008-0418-0","volume":"16","author":"L Costa","year":"2008","unstructured":"Costa L, Badia X, Chow E et al (2008) Impact of skeletal complications on patients\u2019 quality of life, mobility, and functional independence. Support Care Cancer 16:879\u2013889","journal-title":"Support Care Cancer"},{"key":"1797_CR31","doi-asserted-by":"publisher","DOI":"10.1177\/2333393617742282","volume":"4","author":"C Bradshaw","year":"2017","unstructured":"Bradshaw C, Atkinson S, Doody O (2017) Employing a qualitative description approach in health care research. Glob Qual Nurs Res 4:2333393617742282","journal-title":"Glob Qual Nurs Res"},{"key":"1797_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-9-52","volume":"9","author":"MA Neergaard","year":"2009","unstructured":"Neergaard MA, Olesen F, Andersen RS, Sondergaard J (2009) Qualitative description - the poor cousin of health research? BMC Med Res Methodol 9:52","journal-title":"BMC Med Res Methodol"},{"key":"1797_CR33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/nur.20362","volume":"33","author":"M Sandelowski","year":"2010","unstructured":"Sandelowski M (2010) What\u2019s in a name? Qualitative description revisited. Res Nurs Health 33:77\u201384","journal-title":"Res Nurs Health"},{"key":"1797_CR34","unstructured":"Qualitative Research & Evaluation Methods"},{"key":"1797_CR35","doi-asserted-by":"publisher","unstructured":"Essentials of Qualitative Inquiry | Maria J Mayan. https:\/\/doi.org\/10.4324\/b23331\/essentials-qualitative-inquiry-maria-mayan","DOI":"10.4324\/b23331\/essentials-qualitative-inquiry-maria-mayan"},{"key":"1797_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2021.114523","volume":"292","author":"M Hennink","year":"2022","unstructured":"Hennink M, Kaiser BN (2022) Sample sizes for saturation in qualitative research: A systematic review of empirical tests. Soc Sci Med 292:114523","journal-title":"Soc Sci Med"},{"key":"1797_CR37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V (2006) Using thematic analysis in psychology. Qual Res Psychol 3:77\u2013101","journal-title":"Qual Res Psychol"},{"key":"1797_CR38","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/capr.12360","volume":"21","author":"V Braun","year":"2021","unstructured":"Braun V, Clarke V (2021) Can I use TA? Should I use TA? Should I not use TA? Comparing reflexive thematic analysis and other pattern-based qualitative analytic approaches. Counselling and psychotherapy research 21:37\u201347","journal-title":"Counselling and psychotherapy research"},{"key":"1797_CR39","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1080\/2159676X.2019.1628806","volume":"11","author":"V Braun","year":"2019","unstructured":"Braun V, Clarke V (2019) Reflecting on reflexive thematic analysis. Qual Res Sport Exerc Health 11:589\u2013597","journal-title":"Qual Res Sport Exerc Health"},{"key":"1797_CR40","doi-asserted-by":"publisher","first-page":"509","DOI":"10.6061\/clinics\/2014(08)02","volume":"69","author":"GN Marta","year":"2014","unstructured":"Marta GN, Del Nero LG, Marta GN et al (2014) Treatment priorities in oncology: do we want to live longer or better? Clinics (Sao Paulo) 69:509\u2013514","journal-title":"Clinics (Sao Paulo)"},{"key":"1797_CR41","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1200\/JCO.2013.53.5948","volume":"32","author":"G Kotronoulas","year":"2014","unstructured":"Kotronoulas G, Kearney N, Maguire R et al (2014) What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. J Clin Oncol 32:1480\u20131501","journal-title":"J Clin Oncol"},{"key":"1797_CR42","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1111\/j.1365-2648.2011.05772.x","volume":"67","author":"E McCaughan","year":"2011","unstructured":"McCaughan E, Parahoo K, Prue G (2011) Comparing cancer experiences among people with colorectal cancer: a qualitative study. J Adv Nurs 67:2686\u20132695","journal-title":"J Adv Nurs"},{"key":"1797_CR43","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afae194","volume":"53","author":"NF Taylor","year":"2024","unstructured":"Taylor NF, Rimayanti MU, Peiris CL et al (2024) Hip fracture has profound psychosocial impacts: a systematic review of qualitative studies. Age Ageing 53:afae194","journal-title":"Age Ageing"},{"key":"1797_CR44","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00223-004-2222-2","volume":"76","author":"R Hasserius","year":"2005","unstructured":"Hasserius R, Karlsson MK, J\u00f3nsson B et al (2005) Long-term morbidity and mortality after a clinically diagnosed vertebral fracture in the elderly-a 12- and 22-year follow-up of 257 patients. Calcif Tissue Int 76:235\u2013242","journal-title":"Calcif Tissue Int"},{"key":"1797_CR45","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1016\/S0140-6736(25)01385-6","volume":"406","author":"C Ye","year":"2025","unstructured":"Ye C, Ebeling P, Kline G (2025) Osteoporosis. Lancet 406:2003\u20132016","journal-title":"Lancet"},{"key":"1797_CR46","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-019-0570-9","volume":"14","author":"G Koller","year":"2019","unstructured":"Koller G, Katz S, Charrois TL, Ye C (2019) Glucocorticoid-induced osteoporosis preventive care in rheumatology patients. Arch Osteoporos 14:16","journal-title":"Arch Osteoporos"},{"key":"1797_CR47","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/17446651.2019.1617131","volume":"14","author":"K Hu","year":"2019","unstructured":"Hu K, Adachi JD (2019) Glucocorticoid induced osteoporosis. Expert Rev Endocrinol Metab 14:259\u2013266","journal-title":"Expert Rev Endocrinol Metab"},{"key":"1797_CR48","doi-asserted-by":"publisher","unstructured":"Ye C, Leslie WD (2022) Fracture risk and assessment in adults with cancer. Osteoporos Int. https:\/\/doi.org\/10.1007\/s00198-022-06631-4","DOI":"10.1007\/s00198-022-06631-4"},{"key":"1797_CR49","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1200\/JCO.19.01696","volume":"37","author":"CL Shapiro","year":"2019","unstructured":"Shapiro CL, Van Poznak C, Lacchetti C et al (2019) Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline. J Clin Oncol 37:2916\u20132946","journal-title":"J Clin Oncol"},{"key":"1797_CR50","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1001\/jama.2025.6003","volume":"334","author":"SN Morin","year":"2025","unstructured":"Morin SN, Leslie WD, Schousboe JT (2025) Osteoporosis: A review: A review. JAMA 334:894\u2013907","journal-title":"JAMA"},{"key":"1797_CR51","doi-asserted-by":"publisher","unstructured":"Brom L, Pasman HR, Widdershoven GA et al (2014) Onwuteaka-Philipsen BD. Patients\u2019 preferences for participation in treatment decision-making at the end of life: qualitative interviews with advanced cancer patients. https:\/\/doi.org\/10.1371\/journal.pone.0100435","DOI":"10.1371\/journal.pone.0100435"},{"key":"1797_CR52","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/10775587251316917","volume":"82","author":"M Neshan","year":"2025","unstructured":"Neshan M, Padmanaban V, Fareed N et al (2025) Patient decisional preferences: A systematic review of instruments used to determine patients\u2019 preferred role in decision-making. Med Care Res Rev 82:225\u2013239","journal-title":"Med Care Res Rev"},{"key":"1797_CR53","doi-asserted-by":"publisher","unstructured":"Losi S, Berra CCF, Fornengo R et al (2021) The role of patient preferences in adherence to treatment in chronic disease: a narrative review Serena Losi 1, Cesare Celeste Federico Berra 2, Riccardo Fornengo 3, Dario Pitocco 4. Giovanni Biricolti 15:13\u201320. https:\/\/doi.org\/10.33393\/dti.2021.2342","DOI":"10.33393\/dti.2021.2342"},{"key":"1797_CR54","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3390\/medicina61010153","volume":"61","author":"U Religioni","year":"2025","unstructured":"Religioni U, Barrios-Rodr\u00edguez R, Requena P et al (2025) Enhancing therapy adherence: Impact on clinical outcomes, healthcare costs, and patient quality of life. Medicina (Kaunas) 61:153","journal-title":"Medicina (Kaunas)"},{"key":"1797_CR55","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.3390\/diagnostics15151972","volume":"15","author":"A Ardelean","year":"2025","unstructured":"Ardelean A, Tit DM, Furau R et al (2025) Beyond bone mineral density: Real-world fracture risk profiles and therapeutic gaps in postmenopausal osteoporosis. Diagnostics (Basel) 15:1972","journal-title":"Diagnostics (Basel)"},{"key":"1797_CR56","doi-asserted-by":"publisher","unstructured":"Li VKC, Cosgrove S, Collins K, et al (2026) Management of bone health in cancer survivorship: a systematic review of clinical guidelines. Osteoporos Int. https:\/\/doi.org\/10.1007\/s00198-026-07924-8","DOI":"10.1007\/s00198-026-07924-8"},{"key":"1797_CR57","doi-asserted-by":"publisher","first-page":"E639","DOI":"10.1503\/cmaj.221219","volume":"195","author":"G Th\u00e9riault","year":"2023","unstructured":"Th\u00e9riault G, Limburg H, Klarenbach S et al (2023) Recommendations on screening for primary prevention of fragility fractures. CMAJ 195:E639\u2013E649","journal-title":"CMAJ"},{"key":"1797_CR58","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11914-023-00777-8","volume":"21","author":"E Dent","year":"2023","unstructured":"Dent E, Daly RM, Hoogendijk EO, Scott D (2023) Exercise to prevent and manage frailty and fragility fractures. Curr Osteoporos Rep 21:205\u2013215","journal-title":"Curr Osteoporos Rep"},{"key":"1797_CR59","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s43465-025-01356-y","volume":"59","author":"SS Jha","year":"2025","unstructured":"Jha SS (2025) Fragility fracture: 10 commandments. Indian J Orthop 59:244\u2013255","journal-title":"Indian J Orthop"},{"key":"1797_CR60","first-page":"D8209","volume":"168","author":"T Merlijn","year":"2024","unstructured":"Merlijn T, Elders PJM, van der Horst HE (2024) Fracture prevention: breaking with the guideline? Ned Tijdschr Geneeskd 168:D8209","journal-title":"Ned Tijdschr Geneeskd"},{"key":"1797_CR61","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1001\/jamaoncol.2024.4318","volume":"10","author":"C Ye","year":"2024","unstructured":"Ye C, Leslie WD, Al-Azazi S et al (2024) Fracture risk prediction using the Fracture Risk Assessment Tool in individuals with cancer. JAMA Oncol 10:1554\u20131560","journal-title":"JAMA Oncol"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-026-01797-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-026-01797-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-026-01797-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:03:52Z","timestamp":1792796632000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-026-01797-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1797"],"URL":"https:\/\/doi.org\/10.1007\/s11657-026-01797-4","relation":{},"ISSN":["1862-3514"],"issn-type":[{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"16 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"147"}}